Skip to content
Study details
Enrolling now

Psilocybin rTMS for Treatment Resistant Depression

University of Texas at Austin
NCT IDNCT06132178ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

100

Study length

about 6 years

Ages

22–65

Locations

1 site in TX

About this study

This trial is testing whether giving psilocybin after a short, brain stimulation treatment (aiTBS) can help people with depression that hasn't responded to other treatments. The goal is to see if this combination is safe and works.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Low-dose psilocybin
  • 2.Take Psilocybin
  • 3.Use Accelerated intermittent theta burst (aiTBS) rTMS treatment
  • +1 more
PhasePhase 2
DrugLow-dose psilocybin
Routeoral
Primary goalMontgomery Asberg Depression Rating Scale (MADRS)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug routes

oral

Endpoints

Primary: Montgomery Asberg Depression Rating Scale (MADRS)

Secondary: Beck Depression Inventory II (BDI II), Columbia-Suicide Severity Rating Scale (C-SSRS), Discontinuation Emergent Signs and Symptoms Scale, Generalized Anxiety Disorder 7 (GAD-7), Mood and Anxiety Symptom Questionnaire 30 item Anhedonic Depression subscale (MASQ-30), Mood and Anxiety Symptom Questionnaire 30 item Anxious Arousal subscale (MASQ-30), Physicians Health Questionnaire 9 (PHQ-9), Quick Inventory of Depressive Symptom Self-Report (QIDS-SR)

Devices

therapeutic

Body systems

Psychiatry / Mental Health